Search company, investor...



Acquired | Acquired

Total Raised




About EpiTherapeutics

EpiTherapeutics is developing novel innovative cancer drugs based on the world leading research in epigenetics conducted by Professor Kristian Helin and his group at Biotech Research & Innovation Centre (BRIC) at University of Copenhagen. EpiTherapeutics' development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. Subsequent developments may identify other potential clinical indications outside oncology.

Headquarters Location

Ole Maaløesvej 3

Copenhagen, DK-2200,


(+45) 20 25 35 60

Missing: EpiTherapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: EpiTherapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing EpiTherapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

EpiTherapeutics is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest EpiTherapeutics News

瞄准精准医学市场,「HKG Epitherapeutics」想帮助疾病早筛查、早诊断

Dec 9, 2019

随着技术日益成熟,肿瘤早筛成为资本市场值得关注的趋势。特别是今年肿瘤早筛的融资数目得到了较大提升,上半年全球主要市场融资数量为22笔。 36氪近期接触的「HKG Epitherapeutics」,正是肿瘤早筛领域值得关注的企业。 HKG公司共有三个产品线,大多数为全球独家产品:癌症早筛产品基于“DNA甲基化+二代测序平台”,共14个通过血液进行可溯源早筛产品,面向结肠癌、肺癌(也可唾液)、肝癌、子宫颈癌(也可宫颈抹片)及其他10个癌种,和泛癌种(可判断多个癌种)早筛产品,都分别在研发阶段经历过6000-8000例的数据库验证,准确度、特异性、敏感性对早中晚期各类肿瘤绝大多数都在90%以上。 精神病学早筛产品共有两个,分别是血液老年痴呆症早筛、唾液抑郁症筛查。第三个产品线是健康管理产品,它属于消费级基因检测服务,是用唾液检测用户生理年龄(身体真实衰老情况)。 目前,所有产品均已完成研发工作,部分产品(生理年龄、肝癌)已经在美国、加拿大、中国香港开始了试销售,部分还在继续加大人体临床研究样本量来进一步优化产品。 HKG公司的优势是,在“DNA甲基化+NGS”细分领域业内,产品线非常丰富完整,准确度高(绝大多数可以做到90%以上),成本在业内非常低(150元左右/每次检测),目前在中国香港政府的大力资助下正在进行全自动化研发。自动化流程已设计完成,目前主要是机器人编程与联网验证工作。预计2020年底自动化后,成本可以从150元降到50人民币元,检测周期从5.5天降到2天。 其中肝癌早筛产品 epi Liver 是利用白细胞里的DNA甲基化点位进行肝癌早期(0-1期)筛查的技术,是目前世界上唯一可以通过检测白细胞里的DNA甲基化点位,在早期阶段发现肝癌的技术。HKG 公司联合北京佑安医院进行了相关实验,实验数据已经于2018年在Clinical Epigenetics上发表,肝癌早期筛查准确度达到90%以上。 与肝癌早筛产品 epi Liver 同步在中国香港试销的,是 消费级基因检测产品 epiAge 生理年龄 。HKG 公司 COO 马力先生表示,目前试销表现良好。 团队配置是 HKG 公司的核心竞争力。创始人摩西 · 西夫院士(Moshe Szyf)是加拿大皇家科学院院士、加拿大健康科学院院士、美国FDA特聘讲师,葛兰素史克加拿大药理学主席,表观遗传学领域论文量与论文质量都世界排名第一的科学家。摩西 · 西夫院士于20世纪80年代提出表观遗传学可以全面监控人体状况,而后直到2004年,此领域的论文大多数均来自其团队,2004年后学术界开始承认这个细分领域的先进性,有越来越多的团队发表该细分领域的论文,大约2013年前后产业界才开始大规模介入此领域。 该公司已经建设了两处科研实验室,分别位于香港科学园和广州生物岛园区,用于持续研发、临床试验、检测技术全自动化。 为了更好地满足市场需求,该公司需要扩充产能,从百级实验室检测服务阶段过渡到十万级以上大规模检测服务的阶段,因此正在寻求A轮融资,目标融资额为500万美元,以提高在香港或广州的产能。该公司计划于2021年底前向港交所提交IPO申请。 原创文章,作者:梦想家菜菜。转载或内容合作请点击  转载说明  ,违规转载法律必究。

EpiTherapeutics Frequently Asked Questions (FAQ)

  • Where is EpiTherapeutics's headquarters?

    EpiTherapeutics's headquarters is located at Ole Maaløesvej 3, Copenhagen.

  • What is EpiTherapeutics's latest funding round?

    EpiTherapeutics's latest funding round is Acquired.

  • How much did EpiTherapeutics raise?

    EpiTherapeutics raised a total of $29.09M.

  • Who are the investors of EpiTherapeutics?

    Investors of EpiTherapeutics include Gilead Sciences, SEED Capital, Lundbeckfond Ventures, M Ventures, Novo Holdings and 3 more.

  • Who are EpiTherapeutics's competitors?

    Competitors of EpiTherapeutics include Metabolon, MicuRx Pharmaceuticals, Achaogen, SciTech Development, DiscoverX and 14 more.

Compare EpiTherapeutics to Competitors


SULFIDRIS, a spin-off of Milan University, is a drug-discovery company. nSULFIDRIS is focused in R&D of drugs (SULFIDRACs) for the treatment of cancer disorders. nSULFIDRACs are multi-modal safe and effective drugs, capable to act on redox-imbalance-related pathogenetic mechanisms.

IITRI Drug Discovery Division

IIT Research Institute (IITRI) is a contract research organization (CRO) that aims to provide non-clinical toxicology and other drug development services to government and industry. IITRI offers particular expertise in oncologics drug development, inhalation toxicology and technology, carcinogenesis and cancer prevention, and biodefense. IITRI's Drug Discovery Division is a research-based group whose focus is the design and synthesis of new small molecule therapeutics for cancer and infectious disease.

Echelon Biosciences Logo
Echelon Biosciences

Echelon Biosciences is a company that received a SBIR Phase I grant for a project entitled: Near Infrared Substrates for Imaging Autotaxin Activity In Vivo. Their project aims to synthesize ATXRed, an in vivo imaging agent that is specifically activated by the enzymatic activity of autotaxin. Autotaxin is an extracellular enzyme that generates the phospholipid growth factor lysophophatidic acid (LPA). LPA is involved in a variety of biological functions, such as angiogenesis, wound healing, brain development, immunological competence and the regulation of blood pressure. Both LPA and autotaxin have also been implicated in numerous diseases, especially metastatic cancer. Autotaxin was identified as one of the 40 most induced genes in aggressive breast cancer. The broader impacts of this research are the discovery and commercialization of tools that easily highlight specific biological pathways in living organisms. ATXRed will be welcomed by basic researchers in many fields associated with autotaxin and LPA. However, the utility extends beyond the basic research sphere. ATXRed smart probes could also aid pharmaceutical researchers searching for pharmacological inhibitors of autotaxin and LPA receptor agonists and antagonists. ATXRed would be a powerful tool in many rodent models of human cancer. In vivo autotaxin imaging probes could also aid in the clinic by helping to identify and monitor disease progression and treatment. Ultimately, ATXRed could help guide surgical resection of tumorstumors previously identified by the smart probe to have elevated autotaxin activity. In total, ATXRed probes have the potential to impact basic research, drug discovery and the clinic as a prime example of molecular medicine applied from bench to bedside.

Trana Discovery Logo
Trana Discovery

Trana Discovery, a drug discovery technology company, aims to help its partners find classes of drugs for the treatment of serious viral, fungal, and bacterial infectious diseases. The technology identifies compounds that work through a mechanism of action: inhibition of the target pathogen's ability to use transfer RNA (tRNA) essential for protein synthesis or replication. The use of Trana Discovery technology can unlock the value " scientific, human, and financial " hidden in drug compound libraries, expedite the discovery of drugs, and provide opportunities for exclusive rights to drug classes.

Molecular LogiX

Molecular LogiX (MLX) is a drug discovery company located in The Woodlands, Texas, that seeks to discover therapeutics through the application of rationale protein engineering technologies. The company is currently developing protein-based drugs to treat cancer by interfering with established tumor growth factor pathways.

Metabolon Logo

Metabolon is a health technology company focused on metabolomics. It offers a tool for precision medicine and life sciences research. The company's platforms and informatics deliver biomarker discoveries, diagnostic tests, and partnerships in genomics-based, health initiatives. Metabolon was founded in 2000 and is based in Morrisville, North Carolina.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.